<span item_type="fundamental" item_id="1e7f384f15e3e19725c2024a5e4639f3" counter_id="ST/US/NAOV" env="prod"></span><span item_type="announcement" item_id="582805040989145473" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 722 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.91.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 598 K.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>NanoVibronix</strong>: $1,738 thousand for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li><li><strong>ENvue</strong>: $503 thousand for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit</strong>: $523 thousand for the nine months ended September 30, 2025, compared to $1,225 thousand for the same period in 2024, a decrease of 57%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li><li><strong>Operating Loss</strong>: $8,075 thousand for the nine months ended September 30, 2025, compared to $2,212 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $6,696 thousand for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $12,820 thousand for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Goodwill</strong>: $38,631 thousand as of September 30, 2025, resulting from the ENvue merger.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue its operations through its subsidiaries, focusing on non-invasive biological response-activating devices and enteral feeding medical devices. The company expects to incur future net losses and will depend on raising additional funds to support its operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has identified inaccuracies in its 510(k) application for the PainShield MD Plus product and has decided to halt future sales of this product.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326706/000149315225023542/form10-q.htm"></span></li></ul>

NAOV

NanoVibronix | 10-Q: FY2025 Q3 Revenue: USD 722 K